{"id":"naliri","safety":{"commonSideEffects":[{"rate":"30-40%","effect":"Diarrhea"},{"rate":"20-30%","effect":"Fatigue"},{"rate":"20-30%","effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"NALIRI works by inhibiting the activity of PI3K, a key enzyme in the PI3K/AKT/mTOR pathway, which is involved in cell growth and survival. This inhibition leads to a decrease in the activity of AKT and mTOR, resulting in anti-tumor effects.","oneSentence":"NALIRI is a small molecule that targets the PI3K/AKT/mTOR pathway.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:16.324Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors"}]},"trialDetails":[{"nctId":"NCT07099794","phase":"PHASE2","title":"A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen","status":"NOT_YET_RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2025-08-01","conditions":"Biliary Tract Cancer (BTC)","enrollment":90},{"nctId":"NCT07092306","phase":"PHASE2","title":"A Randomized Controlled Study Comparing the Safety and Efficacy of Irinotecan Hydrochloride Liposome Injection Combined With Temozolomide and Vincristine (NALIRI-VT) Versus Irinotecan Combined With Temozolomide and Vincristine (VIT) in Patients With Advanced Ewing's Sarcoma","status":"NOT_YET_RECRUITING","sponsor":"Tang Xiaodong","startDate":"2025-08-10","conditions":"Ewing's Sarcoma","enrollment":74},{"nctId":"NCT07074353","phase":"PHASE3","title":"Irinotecan Liposomes in Total Neoadjuvant Therapy in Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2025-07-20","conditions":"Locally Advanced Rectal Cancer","enrollment":360},{"nctId":"NCT05472259","phase":"PHASE2","title":"A Study Evaluating the Efficacy of 5-FU + NALIRI and 5-FU + NALIRINOX for PDAC (NALPAC)","status":"RECRUITING","sponsor":"Belgian Group of Digestive Oncology","startDate":"2022-05-25","conditions":"Metastatic Pancreatic Ductal Adenocarcinoma","enrollment":134},{"nctId":"NCT06405490","phase":"PHASE2","title":"NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2024-04-17","conditions":"Nanoliposomal Irinotecan, Cadonilimab, Oxaliplatin","enrollment":30},{"nctId":"NCT06006728","phase":"","title":"Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy","status":"COMPLETED","sponsor":"University Hospital, Bordeaux","startDate":"2023-10-06","conditions":"Pancreatic Adenocarcinoma Metastatic","enrollment":58}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":145,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"NALIRI","genericName":"NALIRI","companyName":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","companyId":"cancer-institute-and-hospital-chinese-academy-of-medical-sciences","modality":"Small molecule","firstApprovalDate":"","aiSummary":"NALIRI is a small molecule that targets the PI3K/AKT/mTOR pathway. Used for Advanced solid tumors.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}